ClinicalTrials.gg
RecruitingNCT05680558Updated Apr 27, 2026

Photopheresis in Early-stage Mycosis Fungoides

A Phase 2 interventional study of UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis and THERAKOS® CELLEX photopheresis system in Cutaneous T Cell Lymphoma and Mycosis Fungoides, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-27.

Primary conditionMycosis FungoidesRegistry: Lymphoma, T-Cell, CutaneousReclassifiedWhy we changed it
Registry
Lymphoma, T-Cell, Cutaneous — the first condition term the registry derived for this study.
ClinicalTrials.gg
Mycosis Fungoides
Why
  1. The study's listed conditions name Mycosis Fungoides, a narrower term within Lymphoma, T-Cell, Cutaneous.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Columbia University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled May 2021, registered Nov 2022).
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.

Planned enrollment
48th of 279
74 · median 32
Started
2021
with 5 others
Phase 2
101 of 360
8 open now
Primary completion
2027-03
later than 10 of 35 live
Registered
341st of 360
by date

Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 48th largest by planned enrollment of the 279 interventional ones that give a count, is one of 6 that started in 2021, is one of 101 in phase 2, reaches primary completion later than 10 of the 35 other live ones, and was the 341st registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Mycosis Fungoides with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently, photopheresis is performed as a palliative treatment for late stage CTCL. However, recent studies have demonstrated that patients with early stage CTCL may have markers in their blood which were previously observed primarily in late stage disease, such as clonal T cell populations. Considering these findings, the study aims to investigate whether photopheresis therapy may be used earlier in the disease course to produce a clinical response.

Read the detailed description

The THERAKOS® CELLEX Photopheresis System is currently FDA approved and indicated for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients not responsive to other forms of treatment. The original studies in CTCL were performed in patients having extensive patch/plaque or erythrodermic stage disease. Therefore, photopheresis is used primarily to treat stage III or IV CTCL. However, studies have shown that 50% of patients with early disease may have clonal T-cells in their peripheral blood if polymerase chain reaction is used to amplify the T-cell receptor gamma gene fragments. Thus, patients who are staged as T1 or T2 who also have slight abnormalities in blood involvement, such as atypical cells seen on blood smear or abnormal flow cytometry may benefit from photopheresis therapy. This study aims to investigate the efficacy of photopheresis therapy in patients with Stage !A, 1B, or IIA CTCL.

03

Conditions studied

  • Cutaneous T Cell Lymphoma
  • Mycosis Fungoides

Browse trials for

Keywords

  • photopheresis
04

In context

Mycosis Fungoides Reclassified

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

This study's planned enrollment of 74 is above the median of 34 across 321 interventional studies indexed under Mycosis Fungoides.

Browse Mycosis Fungoides studies →

Lead sponsor

Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.

Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.

Compared within Mycosis Fungoides, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, T-Cell, Cutaneous. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Who are male or female, over the age of 18 and \<40 kg body weight with adequate veins to provide intravenous access.
  2. Who are willing to adhere to the protocol and sign an Informed Patient Consent Document
  3. Must not be on any other device/drug treatment.
  4. Who have the diagnosis of Mycosis Fungoides (MF) including a skin consistent with MF (atypical epidermotropic or folliculocentric T-cells) with appropriate staging as IA, IB or IIA: T1 or T2 (patches or plaques) with .
  5. With IA stage must demonstrate a minor blood abnormality by morphology/laboratory assessment.
  6. With IIA stage - nodes (1.5 cm) must have lymph node biopsy showing dermatopathic nodes or no involvement.
  7. Must be willing and able to discontinue concomitant medications for MF. Subjects currently taking the following drugs must discontinue medication with the following wash out periods prior to enrollment in the trial: PUVA or UVB Therapy - 4 weeks, topical nitrogen mustard or other topical chemotherapy - 4 weeks, bexarotene capsules or other systemic biologic agent - 3 weeks washout, high dose topical , topical retinoids or immunotherapy - 2 week washout with 1% topical hydrocortisone , oral steroids above 10 mg - 30 day washout, unless subject has Addison's Disease or adrenal insufficiency
  8. Who are to at least one of the standard therapies used to treat Stage IA, IB or IIA CTCL such as oral steroids, high-dose topical steroids, topical nitrogen mustard, Bexarotene, PUVA therapy, electron beam radiation, biological response modifiers or oral methotrexate.
  9. Must be willing to abstain from therapeutic sunbathing, phototherapy, tanning beds, etc. for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Who have MF (T3 cutaneous tumors or T4 exfoliative erythroderma) Stage IIB - IVB
  2. Who are unable to tolerate extracorporeal volume loss i.e., severe cardiac disease/anemia
  3. With deterioration of renal function who have a serum creatinine level greater than 3.0 mg/dL.
  4. With lipemic plasma >500 ng/dL, uncontrolled diabetes, history of liver damage (2.5 x normal (ALT), aspartate aminotransferase (AST), porphyria, lupus, positive tests for (HIV) antibody, virus (HCV) antibody or Surface Antigen, severe emotional, behavioral or psychiatric problems that, in the opinion of the investigator, would result in poor compliance with the treatment regimen, and idiosyncratic or reactions to 8-methoxypsoralen compounds, heparin, or citrate.
  5. On oral prednisone therapy or high potency topical .
  6. Who are pregnant or nursing a child.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    UVA Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis System

    TREATMENT with THERAKOS® CELLEX Photopheresis System on two consecutive days every 2 weeks for the first 3 months; then once per month for following 9 months.

    Drug: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis · Device: THERAKOS® CELLEX photopheresis system

Interventions

  • DrugUVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis

    Drug page: MethoxsalenStudies of MethoxsalenMethoxsalen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Extracorporeal Photopheresis (ECP)

    Also known as: UVADEX® with THERAKOS® CELLEX Photopheresis

  • DeviceTHERAKOS® CELLEX photopheresis system

    THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system

07

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate at 1 year measured by the modified skin-weighted assessment tool (mSWAT) in accordance with Olsen et al criteria for response in clinical trial. Measurable lesions are defined as those that can be accurately measured in at least one dimension.

    Time frame: 1 Year

Secondary outcomes

  1. Time to Response of Photopheresis Therapy

    The time to response calculated from time of photopheresis treatment initiation to the first objective response (clearance of skin disease from baseline ≥50%) observed for participants who achieved a complete response (CR) (clearing of all disease manifestations confirmed by biopsy) or partial response (PR) (partial response defined as \> 50% improvement in the extent of skin involvement).

    Time frame: 1 Year

  2. Duration of Response

    Duration of response (DOR) will be calculated from time of response to documentation of progression or death.

    Time frame: 1 Year

  3. Change in Functional Assessment of Cancer Therapy - General (FACT-G) Score

    The FACT-G is a 27-item questionnaire designed to measure four health related quality of life in cancer patients. Scores range from 0-108 with a higher score indicating better quality of life.

    Time frame: Baseline and 1 Year

  4. Change in Skindex-29 Score

    The Skindex-29 is a questionnaire with 29 questions that assess the health-related quality of life of patients with skin diseases. Scores range from 0-100 with a higher scoring indicating a worse health status.

    Time frame: Baseline and 1 Year

  5. Change in Short Form Survey (SF-36v2) Score

    The SF-36v2 is a health survey measuring quality of life. Scores range from 0-100 with a higher scoring indicating a better quality of life.

    Time frame: Baseline and 1 Year

  6. Change in Size of Lymph Nodes

    The change in size (single maximum dimension in centimeters) of lymph nodes will be noted as applicable. By definition, the patients should not have pathologically involved lymph nodes.

    Time frame: Baseline and 1 Year

  7. Change in Sézary Cell Counts at 6 and at 12 months

    Change in Sézary cell counts (malignant cells) in blood samples as assessed by flow cytometry. By definition, the enrolled patients will have only minor blood involvement and not leukemia.

    Time frame: Baseline, 6 months and 12 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Mar 2027, 70 months after the start.

Of 33 non-industry phase 2 interventional studies under Mycosis Fungoides, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 119. This study's planned 70 months is close to that.

Counting every sponsor, half of 42 studies reached it within 64 months; a quarter within 39 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2022
First posted
Jan 11, 2023
StartActual
May 8, 2021
Primary completionEst.
Mar 2027
CompletionEst.
Jul 2028
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05680558
Collaborators
Mallinckrodt, Inc.
Responsible party
Larisa Geskin, MD (Director, Cutaneous Oncology, Columbia University) — Principal investigator
First posted
Jan 11, 2023
Start date
May 8, 2021
Primary completion
Mar 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Apr 27, 2026

Study contacts

Larisa Geskin, MD
Contact
ljg2145@cumc.columbia.edu
212-305-5293
Larisa Geskin, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxsalen

Start the discussion